Sirnaomics Management Management

Patrick Lu, Ph.D.
President & CEO
Patrick is the founder and has led Sirnaomics from an early discovery effort to an siRNA therapeutics product company, with multiple programs currently at clinical stage. Patrick brings 25+ years of nucleic acid drug development experience in Novartis, Digene and Intradigm which he was co-founder. He has led raising over $70 million for the company up to now and developing novel siRNA therapeutic, STP705, for treatment of cancer and fibrosis diseases. Patrick is also serving as Chairman of the Board of Directors of the Company.
Michael Molyneaux, M.D., MBA
Chief Medical Officer
Mike brings a unique background with 20 years of experience in clinical medicine and direct patient care combined with 15 years experience in clinical trial development. Mike is a board certified Medical Doctor and has completed his MBA. He was previously the CMO of Macrocure, a late stage clinical company that completed successful IPO in fall of 2014. Mike’s role is to help define therapeutic programs that will match the key properties of our lead product candidates. He is responsible for Global Clinical Operations, Regulatory Affairs, and Medical Affairs. Mike is also a member of the Sirnaomics Board of Directors.
David Evans, Ph.D.
Chief Scientific Officer
David has 20+ years’ experience building and leading scientific research teams focused on target/drug discovery and early stage drug development efforts in Oncology at companies including Millennium Pharmaceuticals, Serono Pharmaceuticals, TGEN Cancer Drug Development Lab, and at Dharmacon. His role at Sirnaomics is to initiate new therapeutic programs based on the most advanced RNAi technologies, identify lead compounds, mature those through pre-clinical proof-of-mechanism (pPOM) and proof-of-concept (pPOC) studies toward nomination of the candidates for clinical development.
Dmitry Samarsky, Ph.D.
Chief Technology Officer
Dmitry is a recognized expert in RNAi technology and brings 15+ year of scientific, technology and business development leadership experience at RNAi companies in the US, Asia and Europe. Most recently he served as a Chief Scientific Officer at Silence Therapeutics (UK, Germany). Dmitry’s role is to secure Sirnaomics’ position as leader in RNAi technology, and to initiate and facilitate pharma partnering discussions.
Allan L. Shaw, CPA
Chief Financial Officer
Allan is a highly regarded biopharma executive and board member, who brings 20+ years of extensive senior global strategic, financial, M&A, operational, capital markets and governance experience. Notably, he has led raising more than $4 billion in public/private financings (including two IPOs). Most recently, Mr. Shaw took Syndax Pharmaceuticals, Inc. public as its Chief Financial Officer. Mr. Shaw has also served as the Chief Financial Officer of Serono S.A. (third largest global biotechnology company). He also formerly had a monthly column in Life Science Leader magazine entitled “Deeper Dive – a CFO insider’s view of the issues impacting our industry” and has contributed to several corporate governance books.
George Ji, MBA
Chief Operation Officer
George has 25+ years of industrial business development and corporate management experience at international firms, including GE, ASME and Quantum Communications. Prior to joining Sirnaomics, George served as a managing director of China Biopharm, Inc., a US listed bio-pharmaceutical company, being responsible for its corporate affairs and US operations. In his current role, George manages general operation of the company, including finance and accounting, human resources and general administration.
Nigel Yip
Vice President, Corporate Finance
Nigel has 10+ years of transaction experiences in merger & acquisitions, initial public offerings, and private equity. Prior to joining Sirnaomics, Nigel served as a vice president in the Credit Suisse’ investment banking team, and later transferred to Credit Suisse’ private equity team covering growth equity opportunities across healthcare, consumer, and technology sectors in Asia Pacific. In his current role, Nigel manages the overall fundraising process of the group and communication with the banking and investor communities.
John Buergenthal, MBA, SPHR
Vice President, Human Resources
John has 25+ years of human resource management experience with a focus in the biopharmaceutical industry. Prior to joining Sirnaomics, John led the human resources function for two public companies, Guilford Pharmaceuticals, and PharmAthene, and most recently led the human resources function at Ameritox, LLC. In his past leadership roles, John has focused on building and growing talent management programs for high growth and emerging biopharmaceutical companies. John is responsible for the development of all HR and talent management functions in his current position with the Company.